LIFE SCIENCES CONSULTING PARTNERS (LSCP) BECOMES SAFE-BIOPHARMA VENDOR PARTNER

Fort Lee, N.J. & Zurich, Switzerland (January 28, 2009) -- Life Sciences Consulting Partners (LSCP), a global consultancy providing a variety of strategic services related to International Conference on Harmonization (ICH) standards and regional regulatory authorities, has become a vendor partner of SAFE-BioPharma Association. SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma™ digital identity and signature standard for the biopharmaceutical and healthcare industries.
“LSCP’s knowledge of global industry processes and regional regulators will be useful to SAFE-BioPharma member companies seeking to implement use of the SAFE-BioPharma standard in the EU and other jurisdictions. The firm’s broad range of expertise will be a valuable resource to companies transitioning to more complete electronic environments,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association. 
LSCP has extensive experience with the Food and Drug Administration (FDA), European Medicines Agency (EMEA), EU National Competent Authorities, and Japan’s Ministry of Health, Labor and Welfare (MHLW). 
LSCP’s numerous areas of expertise include risk management of non-compliance and submission types including all eCTD-formatted submissions; eLabeling (PIM, SPL); pharmacovigilance; drug safety reporting (ADR, ICSR, etc.); XML Authoring, and eDiscovery. Among its areas of specialization, LSCP advises organizations on the use of the SAFE-BioPharma standard to manage digital identities and to assist in implementing globally-compliant digital signatures.

About LSCP
LSCP is a well established global network of Subject Matter Experts (SME), helping global Life Sciences companies and national health systems and organizations to improve their processes by applying international standards through the controlled transition from paper to electronic systems, implementing interoperability in a transparent, step-by-step approach.  To learn more, visit www.lsconsultingpartners.com.

About SAFE-BioPharma Association
SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma’s vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association’s members include Abbott (NYSE: ABT), Amgen (NASDAQ: AMGN), AstraZeneca (NYSE: AZN), Bristol-Myers Squibb (NYSE:BMY), GlaxoSmithKline (NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), Merck (NYSE:MRK), National Notary Association, Schering-Plough Organon (NYSE: SGP), Pfizer (NYSE: PFE), Premier Inc., Procter & Gamble (NYSE: PG), Roche and Sanofi-Aventis (NYSE:SNY). For more information, visit www.safe-biopharma.org.

SAFE-BioPharma™ is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from
SAFE-BioPharma Association.